LPL Financial
ADCT icon

LPL Financial’s ADC Therapeutics ADCT Stock Holding History

LPL Financial’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9K Sell
10,165
-1,735
-15% -$5.06K ﹤0.01% 6167
2026
Q1 		$44.6K Sell
11,900
-20,000
-63% -$78.8K ﹤0.01% 5797
2025
Q4 		$113K Sell
31,900
-13,200
-29% -$53.6K ﹤0.01% 5578
2025
Q3 		$180K Buy
45,100
+100
+0.2% +$315 ﹤0.01% 5382
2025
Q2 		$121K Buy
45,000
+20,000
+80% +$42.1K ﹤0.01% 5227
2025
Q1 		$35.3K Hold
25,000
– – ﹤0.01% 5191
2024
Q4 		$49.8K Buy
+25,000
New +$65.4K ﹤0.01% 5101

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LPL Financial's ADCT Position: Q2 2026 in Review

LPL Financial reduced its ADC Therapeutics (ADCT) stake by 15% in Q2 2026, selling an estimated $5.06K and leaving 10,165 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6167.

LPL Financial first reported a position in ADCT in Q4 2024 and has held it in 7 quarters since. The position peaked at $180K in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • LPL Financial held 10,165 shares of ADC Therapeutics worth $10.9K as of Q2 2026.
  • LPL Financial sold 1,735 ADC Therapeutics shares in Q2 2026, an estimated $5.06K.
  • ADC Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #6167 holding.
  • LPL Financial first reported a position in ADC Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • LPL Financial's ADC Therapeutics position peaked at $180K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.